前立腺癌における血清 Basic Fetoprotein の臨床的意義 PAP・γ-Sm・PSAとの比較検討

後藤 章暢; 水野 禄仁; 武中 篤; 川井田 徳之; 郷司 和男; 小川 隆義; 荒川 創一; 守殿 貞夫; 原田 健次; 広岡 九兵衛; 島谷 昇; 井上 隆朗; 田中 宏和; 梅津 敬一; 松井 隆; 稲葉 洋子; 泉 武寛; 山田 裕二; 伊藤 登; 岡本 恭行; 岡田 弘; 源吉 顕治; 石井 勝; Hitoshi Nagata; Nozomu Yamanaka; Hiroshi Maeda; Tateo Nakanishi; Hideki Uehara

doi:10.5980/jpnjurol1989.82.467

CLINICAL EVALUATION OF SERUM BASIC FETOPROTEIN FOR PROSTATIC CANCER

Comparative Study with PAP, γ-Sm and PSA

Akinobu Gotoh, Yoshihito Mizuno, Atsushi Takenaka, [in Japanese], Kazuo Gohji, Takayoshi Ogawa, Soichi Arakawa, Sadao Kamidono, Kenji Harada, Kuhei Hirooka, Noboru Shimatani, Takaaki Inoue, Hirokazu Tanaka, Keiichi Umezu, Takashi Matsui, Youko Inaba, Takehiro Izumi, Yuuji Yamada, Noboru Ito, Yasuyuki Okamoto, Hiroshi Okada, Kenji Minayoshi, Masaru Ishii, Hitoshi Nagata, Nozomu Yamanaka, Hiroshi Maeda, Tateo Nakanishi, Hideki Uehara

Author information

Akinobu Gotoh
Department of Urology, Kobe University School of Medicine
Yoshihito Mizuno
Department of Urology, Kobe University School of Medicine
Atsushi Takenaka
Department of Urology, Kobe University School of Medicine
[in Japanese]
Department of Urology, Kobe University School of Medicine
Kazuo Gohji
Department of Urology, Kobe University School of Medicine
Takayoshi Ogawa
Department of Urology, Kobe University School of Medicine
Soichi Arakawa
Department of Urology, Kobe University School of Medicine
Sadao Kamidono
Department of Urology, Kobe University School of Medicine
Kenji Harada
Department of Urology, Kanebo Memorial Hospital
Kuhei Hirooka
Department of Urology, Kansai Rosai Hospital
Noboru Shimatani
Department of Urology, Kansai Rosai Hospital
Takaaki Inoue
Department of Urology, Kansai Rosai Hospital
Hirokazu Tanaka
Department of Urology, Kansai Rosai Hospital
Keiichi Umezu
Department of Urology, Kobe National Hospital
Takashi Matsui
Department of Urology, Kobe National Hospital
Youko Inaba
Department of Urology, Kobe National Hospital
Takehiro Izumi
Department of Urology, Kasai City Hospital
Yuuji Yamada
Department of Urology, Kasai City Hospital
Noboru Ito
Department of Urology, Shakaihoken Kobe Chuo Hospital
Yasuyuki Okamoto
Department of Urology, Shakaihoken Kobe Chuo Hospital
Hiroshi Okada
Department of Urology, Miki City Hospital
Kenji Minayoshi
Department of Urology, Miki City Hospital
Masaru Ishii
Department of Laboratory Medicine, Saitama Cancer Center
Hitoshi Nagata
Department of Urology, Takasago City Hospital
Nozomu Yamanaka
Department of Urology, Shinko Clinic
Hiroshi Maeda
Department of Urology, Shinko Clinic
Tateo Nakanishi
Department of Urology, Kawachi General Hospital
Hideki Uehara
Department of Urology, Shakaihoken Kobe Chuo Hospital

Keywords: prostatic cancer, BFP, tumor marker

JOURNAL FREE ACCESS

1991 Volume 82 Issue 3 Pages 467-472

DOI https://doi.org/10.5980/jpnjurol1989.82.467

Details

Abstract

The clinical significance of serum basic fetoprotein (BFP) in prostatic cancer was investigated together with serum prostatic acid phosphatase (PAP), γ-seminoprotein (γ-Sm) and prostate specific antigen (PA).
Investigated in this study were 40 patients with prostatic cancer, ranging in age from 50 to 85 years (mean age: 69.5 years). According to clinical staging, 3 cases (7.5%) had a stage A disease, 10 cases (25.0%) a stage B disease, 7 cases (17.5%) a stage C disease, and 20 cases (50.0%) a stage D disease. The positive rates for serum BFP, PAP, γ-Sm, and PSA were 60.0, 45.0, 63.6, and 68.4%, respectively, and these rates increased as the stage advanced. The above results suggest that BFP is the most useful marker of the four for monitoring prostatic cancer.
In a combination assay of these four markers, 29 (87.9%) of 33 patients with prostatic cancer could be diagnosed by observing an elevated serum level in one of the markers. This suggests that a combination assay of BFP, PAP, γ-Sm and PSA in patients with prostatic cancer is useful for diagnosis and monitoring of the disease.

Corresponding author

Register with J-STAGE for free!